Haematopoietic stem cells therapy (HSCT) is a recognised treatment in multiple sclerosis (MS) especially in highly active cases despite first line therapy. In some cases of rapidly evolving MS, HSCT has been tried as first line treatment with good outcome. Active progressive MS cases are also considered on individual basis at a multidisciplinary setting.

The aim of the treatment is to reset the immune system, this in turn help reduce inflammation in brain and/or spinal cord, may aid recovery from recent relapse related symptoms, and hopefully prevent disability progression.

Factors taken into consideration during the assessment are: age, duration of disease, type of MS, disability level (EDSS score), MRI scan findings, previous immune modulatory treatments, and medical comorbidities.

Dr Falah is a member of the pan London MDT group which approves HSCT treatment in NHS and private settings (the latter takes place at HCA London Bridge Hospital in collaboration with the Haematology Team). If you would like to learn more about HSCT use in MS, book a clinic consultation with Dr Falah.